Chemotherapy Research and Practice / 2012 / Article / Tab 1

Review Article

Advances in Targeting HER3 as an Anticancer Therapy

Table 1

HER3-targeted drugs under development.

DrugTypeTarget(s)Development phaseSponsor

MM-121Humanized mAbHER3Phase I/IIMerrimack
U3-1287 (AMG 888)Humanized mAbHER3Phase IU3 Pharma GmbH
MM-111Bispecific antibodyHER2-HER3Phase IMerrimack
PertuzumabHumanized mAbHER2-HER3Phase IIIGenentech
MEHD7945AmAbHER1, HER3Phase IIGenentech
MP-470 (Amuvatinib)Pan inhibitorHER1/2/3Phase IIAstex Pharmaceuticals
AZD8931Pan inhibitorHER1/2/3Phase I/IIAstraZeneca

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.